FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 508 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer EMA Recommends Extension of Therapeutic Indications for Asciminib NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable for Reaching High-Risk and Underserved Populations MOST POPULAR FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer April 14, 2021 EMA Recommends Extension of Indications for Osimertinib December 18, 2024 Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... November 15, 2024 Ivonescimab Plus Chemotherapy Significantly Improves PFS in Patients with NSCLC Previously... June 19, 2024 Load more HOT NEWS Twins Born 15 Minutes Apart Have Birthdays In Different Years For Children with Retinoblastoma, Disparities Seen across the Globe HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors
